Printer Friendly

GENETICS INSTITUTE PLEASED WITH BAXTER AND RHONE-POULENC RORER FACTOR VIII PATENT SETTLEMENT

 CAMBRIDGE, Mass., May 12 /PRNewswire/ -- As previously announced today by Baxter International, (NYSE: BAX) Baxter, Rhone-Poulenc Rorer (NYSE: RPU) and The Scripps Research Institute, have settled a six-year old patent lawsuit concerning Factor VIII concentrates. The settlement, to be filed in the U.S. District Court of Delaware, relates to both plasma-derived and recombinant Factor VIII products.
 Baxter is Genetics Institute's (NASDAQ: GENIZ) exclusive worldwide licensee for recombinant Factor VIII under Genetics Institute's patent and technology rights. Recombinate AHF is the result of more than a 10- year research and development collaboration between Baxter and Genetics Institute. Genetics Institute manufactures recombinant AHF concentrate, the drug substance used in Recombinate AHF, for Baxter.
 As part of the settlement, Rhone-Poulenc Rorer has signed a long- term agreement with Baxter regarding, among other things, the supply of recombinant AHF concentrate.
 Genetics Institute may earn additional manufacturing revenue, if Rhone-Poulenc Rorer purchases recombinant AHF concentrate from Baxter. Genetics Institute will not contribute to Baxter's $105 million settlement payment to Rhone-Poulenc Rorer. However, Genetics Institute has agreed to a share in the cost of future royalties to Rhone-Poulenc Rorer on Baxter's sales of Recombinate AHF. This royalty sharing is not expected to have a material effect on Genetics Institute's future results of operations.
 "We are very pleased with this settlement," commented Gabriel Schmergel, president and CEO of Genetics Institute. "Commercial sales of Baxter's recombinant Factor VIII product can continue in countries where it has been approved by regulatory authorities, and commence in countries where it awaits such approval, without further patent challenges from Rhone-Poulenc Rorer. This will ensure a stable supply of recombinant Factor VIII for hemophilia patients."
 Genetics Institute (NASDAQ:GENIZ) is a leading biopharmaceutical firm engaged in the discovery and development of human pharmaceuticals through recombinant DNA and other technologies. The company has a diversified portfolio of licensed and proprietary products at various stages of development, including treatments for anemia, hemophilia, cancer, bone damage, heart disease, inflammatory conditions, and immune system disorders.
 American Home Products Corporation (NYSE:AHP) holds a majority interest in Genetics Institute. AHP is a world leader in the marketing and manufacturing of prescription drugs, medical supplies, diagnostics, over-the-counter medicines and food products.
 -0- 5/12/93
 /CONTACT: Dennis Harp or Gina Brazier, Genetics Institute, Inc. 617-876-1170/
 (GENIZ, BAX, RPU)


CO: Genetics Institute; Baxter International, Rhone-Poulenc Rorer ST: Massachusetts IN: MTC SU:

DJ -- NE015 -- 7816 05/12/93 18:08 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 12, 1993
Words:401
Previous Article:COWLES MEDIA COMPANY APPROVES 6-FOR-1 SPLIT
Next Article:BAXTER, RHONE-POULENC RORER RESOLVE ALL DISPUTES INVOLVING FACTOR VIII:C PATENTS; SIGN PURCHASING AGREEMENT FOR BAXTER PRODUCTS
Topics:


Related Articles
NATIONAL HEMOPHILIA FOUNDATION PETITIONS COURT
RHONE-POULENC RORER RESTATES COMMITMENT TO HEMOPHILIA COMMUNITY FOR UNINTERRUPTED SUPPLY OF FACTOR VIII:C
MARION MERRELL DOW AND RHONE-POULENC RORER REACH AGREEMENT TO SETTLE DISPUTES REGARDING ANTIHYPERTENSIVE DRUGS
COURT DENIES REQUEST FOR PRELIMINARY PATENT INJUNCTION AGAINST HIGHLY PURIFIED FACTOR VIII:C PRODUCT
MILES INC. AND RHONE-POULENC RORER SETTLE PATENT DISPUTE
RHONE-POULENC RORER FILES LAWSUIT AGAINST MARION MERRELL DOW ALLEGING FALSE AND MISLEADING PROMOTION
RHONE-POULENC RORER FILES FOR PELIMINARY INJUNCTION AGAINST MARION MERRELL DOW, ALLEGING FALSE AND MISLEADING PROMOTION
BAXTER, RHONE-POULENC RORER RESOLVE ALL DISPUTES INVOLVING FACTOR VIII:C PATENTS; SIGN PURCHASING AGREEMENT FOR BAXTER PRODUCTS
PARTIAL SETTLEMENT OF UP TO $150 MILLION REACHED IN HEMOPHILIA AIDS CLAIMS AGAINST BAXTER HEALTH CARE CORPORATION AND ARMOUR PHARMACEUTICAL
RHONE-POULENC RORER S.A. FILES PATENT INFRINGEMENT LAWSUIT AGAINST BRISTOL-MYERS SQUIBB REGARDING TAXOL(R)

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters